NonprofitsFoundation For Innovative New Diagnostics Find

Medical Research

Foundation For Innovative New Diagnostics Find

SWITZERLAND

Total revenue

$49.3M

Total expenses

$56.8M

Net assets

$8.6M

Grants received

$8.4M

6 grants

EIN

980407553

Tax year

2024

Mission

The development and implementation of new, low cost diagnostics for infectious diseases for use in low-resource areas.

Programs

3 programs

See schedule O

Expenses: $5.2MGrants: $423K

See schedule O

Expenses: $4.9MGrants: $628K

Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa

Expenses: $22.1MGrants: $5.1M

Financials

FY 2024

Revenue

Contributions & grants$46.6M
Program service revenue
Investment income$2.4M
Other revenue$302K
Total revenue$49.3M

Expenses

Grants paid$12.8M
Salaries & benefits$20.5M
Fundraising$696K
Other expenses$23.5M
Total expenses$56.8M
Total assets$51.3M
Net assets$8.6M

People

26 listed

NameRoleCompensation

MARTA FERNANDEZ SUAREZ

CHIEF TECHNOLOGY OFFICER (thru 10/24)

Board

$286K

40 hrs/wk

SERGIO CARMONA

CHIEF MEDICAL OFFICER (thru 9/24)

Board

$284K

40 hrs/wk

SHARON SAACKS

SENIOR DIRECTOR, PROGRAMME OPERATIONS (thru 7/24)

Board

$231K

40 hrs/wk

NORMA TORRES

CHIEF OPERATING OFFICER (thru 5/24)

Board

$216K

40 hrs/wk

WILLIAM RODRIGUEZ

CHIEF EXECUTIVE OFFICER (thru 6/24)

Board

$198K

40 hrs/wk

CASSANDRA KELLY-CIRINO

VP, HEALTH PROGRAMMES (thru 8/24)

Board

$191K

40 hrs/wk

WILLO BROCK

EXECUTIVE VP, EXTERNAL AFFAIRS (thru 6/24)

Board

$164K

40 hrs/wk

DAYO ADETIFA

CHIEF TRANSFORMATION OFFICER/CEO

Board

$139K

40 hrs/wk

SOUMYA SWAMINATHAN

MEMBER OF THE BOARD (THRU 8/2024)

Board

1 hrs/wk

RICK ARTHUR BRIGHT

MEMBER OF THE BOARD (THRU 8/2024)

Board

1 hrs/wk

PRECIOUS MATSOSO

MEMBER OF THE BOARD

Board

1 hrs/wk

MICHELE COSTAFORLAZ

MEMBER OF THE BOARD

Board

1 hrs/wk

MARCEL TANNER

MEMBER OF THE BOARD

Board

1 hrs/wk

KAMINENI SHOBANA

MEMBER OF THE BOARD

Board

1 hrs/wk

FRUTIGER CHRISTIAN

MEMBER OF THE BOARD

Board

1 hrs/wk

DAVID HEYMANN

MEMBER OF THE BOARD

Board

1 hrs/wk

AYOADE ALAKIJA

CHAIRMAN OF THE BOARD

Board

1 hrs/wk

DARRYL ENGLISH

DEPUTY DIRECTOR, FINANCE (THRU 11/24)

Staff

$343K

40 hrs/wk

BROOKE NICHOLS

SENIOR DIRECTOR, IMPACT

Staff

$265K

40 hrs/wk

BEATRICE MOUTON

DIRECTOR, HUMAN RESOURCES

Staff

$261K

40 hrs/wk

MORTEN RUHWALD

DIRECTOR, TUBERCULOSIS PROGRAMME

Staff

$245K

40 hrs/wk

SHAUKHAT ALI KHAN

Director Strategic Information

Staff

$235K

40 hrs/wk

SANJAY SARIN

VP, ACCESS (thru 10/24)

Staff

$232K

40 hrs/wk

MARIA CECILIA FERREYRA ARELLANO

Director of AMR Programme

Staff

$213K

40 hrs/wk

KEVIN TETTEH

DIRECTOR, MALARIA FEVER PROGRAMME

Staff

$182K

40 hrs/wk

Louisa Chaubert

DIRECTOR OF FINANCE (THRU 12/23)

Staff

$96K

0

Independent contractors

WORLD HEALTH ORGANIZATION

PUBLIC-HEALTH TECHNICAL SUPPORT

$7M

INSTITUTE PASTEUR OF DAKAR

RESEARCH AND LABORATORY DIAGNOSTICS

$4.5M

AIRPLUS INTERNATIONAL

FLIGHT ARRANGMENT SERVICES

$1.3M

GLOBAL FUND GLOBAL HEALTH CAMPUS

OFFICE SPACE PROVIDER

$742K

INTERHYVE SARL

IT SUPPORT SERVICES

$602K

Grants received

Showing 6 of 6

FromAmountPurposeYear
$450K
TO ADVANCE STANDARDS AND CAPACITY FOR IMPROVED HEALTH OUTCOMES IN LOW- AND MIDDLE-INCOME COUNTRIES.
2024
$1.3M
ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT
2023
$50K
TO RUN A SERIES OF CIVIL SOCIETY CONSULTATIONS THAT SUPPORT THE PUBLIC AND PRIVATE SECTORS TO IMPLEMENT THE WORLD HEALTH ASSEMBLY DIAGNOSTICS RESOLUTION ON CLOSING THE DIAGNOSTIC GAPS THAT LEAVE PEOPLE AT RISK OF PREVENTABLE AND TREATABLE ILLNESSES, ENABLING EFFECTIVE DISEASE SURVEILLANCE, AND BUILDING SUSTAINABLE AND RESILIENT HEALTH SYSTEMS
2023
$5M
COVID-19 RELIEF AND RECOVERY
2022
$1.1M
ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT
2022
$500K
To accelerate the identification, development, and evaluation of diagnostics for COVID-19.
2020

Funded by

$8.4M from 5 funders · 6 grants · 2020–2024

The Leona M And Harry B Helmsley

$2.4M · 2 grants · 2022–2023

Foundation To Promote Open Society

$50K · 1 grant · 2023

Details

EIN980407553
NTEE codeH80
Subsection03
Ruling date2003-10
Formed2003
Employees227
Volunteers3
FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND — Mission, Financials & Grants Received | Grantivo